Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 22866897)

1.

PSMA-targeted theranostic nanoplex for prostate cancer therapy.

Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee SR, Winnard PT Jr, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM.

ACS Nano. 2012 Sep 25;6(9):7752-62. Epub 2012 Aug 9.

2.

Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen.

Ley CR, Beattie NR, Dannoon S, Regan M, VanBrocklin H, Berkman CE.

Bioorg Med Chem Lett. 2015 Jun 15;25(12):2536-9. doi: 10.1016/j.bmcl.2015.04.047. Epub 2015 Apr 29.

PMID:
25956413
3.

New tools for the quantitative assessment of prodrug delivery and neurotoxicity.

Samuelson LE, Scherer RL, VanSaun MN, Fan KH, Dozier EA, Carter KJ, Koyama T, Shyr Y, Aschner M, Stanwood GD, Bornhop DJ, Matrisian LM, McIntyre JO.

Neurotoxicology. 2015 Mar;47:88-98. doi: 10.1016/j.neuro.2015.02.005. Epub 2015 Feb 27.

PMID:
25732874
4.

Evaluation of a PSMA-targeted BNF nanoparticle construct.

Behnam Azad B, Banerjee SR, Pullambhatla M, Lacerda S, Foss CA, Wang Y, Ivkov R, Pomper MG.

Nanoscale. 2015 Mar 14;7(10):4432-42. doi: 10.1039/c4nr06069e.

PMID:
25675333
5.

Targeted prodrug approaches for hormone refractory prostate cancer.

Aloysius H, Hu L.

Med Res Rev. 2015 May;35(3):554-85. doi: 10.1002/med.21333. Epub 2014 Dec 22.

PMID:
25529338
6.

Theranostic nanoparticles.

Chen F, Ehlerding EB, Cai W.

J Nucl Med. 2014 Dec;55(12):1919-22. doi: 10.2967/jnumed.114.146019. Epub 2014 Nov 20. Review.

PMID:
25413134
7.

A theranostic "SMART" aptamer for targeted therapy of prostate cancer.

de Franciscis V.

Mol Ther. 2014 Nov;22(11):1886-8. doi: 10.1038/mt.2014.190. No abstract available.

PMID:
25365986
8.

Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.

Byun Y, Pullambhatla M, Wang H, Mease RC, Pomper MG.

Macromol Res. 2013 May 1;21(5):565-573.

9.

Theranostic hybrid molecular imaging.

Gambini JP.

World J Nucl Med. 2014 May;13(2):73-4. doi: 10.4103/1450-1147.139129. No abstract available.

10.

Theranostic nanoemulsions: codelivery of hydrophobic drug and hydrophilic imaging probe for cancer therapy and imaging.

Yang X, Wang D, Ma Y, Zhao Q, Fallon JK, Liu D, Xu XE, Wang Y, He Z, Liu F.

Nanomedicine (Lond). 2014 Dec;9(18):2773-85. doi: 10.2217/nnm.14.50.

PMID:
25000945
11.
12.

Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.

Hao Z, Fan W, Hao J, Wu X, Zeng GQ, Zhang LJ, Nie SF, Wang XD.

Drug Deliv. 2014 Jun 3:1-8. [Epub ahead of print]

PMID:
24892627
13.

Theranostic nanoparticles for future personalized medicine.

Ryu JH, Lee S, Son S, Kim SH, Leary JF, Choi K, Kwon IC.

J Control Release. 2014 Sep 28;190:477-84. doi: 10.1016/j.jconrel.2014.04.027. Epub 2014 Apr 26. Review.

PMID:
24780269
14.

Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model.

Lin Q, Jin CS, Huang H, Ding L, Zhang Z, Chen J, Zheng G.

Small. 2014 Aug;10(15):3072-82. doi: 10.1002/smll.201303842. Epub 2014 Apr 6.

PMID:
24706435
15.

Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.

Huang SS, Wang X, Zhang Y, Doke A, DiFilippo FP, Heston WD.

Prostate. 2014 May;74(7):702-13. doi: 10.1002/pros.22789. Epub 2014 Feb 24.

PMID:
24615708
16.

Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.

Wiehr S, Bühler P, Gierschner D, Wolf P, Rolle AM, Kesenheimer C, Pichler BJ, Elsässer-Beile U.

Prostate. 2014 May;74(7):743-55. doi: 10.1002/pros.22794. Epub 2014 Mar 9.

PMID:
24610028
17.

Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen.

Mukherjee A, Darlington T, Baldwin R, Holz C, Olson S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R, Lupold SE.

ChemMedChem. 2014 Jul;9(7):1356-60. doi: 10.1002/cmdc.201300549. Epub 2014 Mar 3.

18.

Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.

Eder M, Schäfer M, Bauder-Wüst U, Haberkorn U, Eisenhut M, Kopka K.

Prostate. 2014 May;74(6):659-68. doi: 10.1002/pros.22784. Epub 2014 Jan 25.

19.

Applications of nanoparticles in the detection and treatment of kidney diseases.

Brede C, Labhasetwar V.

Adv Chronic Kidney Dis. 2013 Nov;20(6):454-65. doi: 10.1053/j.ackd.2013.07.006. Review.

20.

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.

Ma Q, Gomes EM, Lo AS, Junghans RP.

Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749.

PMID:
24174378
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk